Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Delenex Therapeutics AG

Latest From Delenex Therapeutics AG

Pipeline Watch: Phase III Starts With DCC-2618, Tislelizumab And Tabelecleucel

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Cell Medica Targeting Next CAR-T Wave: Solid Tumor Anticancers

Cell Medica has just raised a large Series C from UK institutional investors to explore the use of novel cell-based immunotherapies in solid tumors, a “new chapter” for this class of therapeutic agents.

Financing ImmunoOncology

Start-Up Execs On The Move, December 2013

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Recent Financings of Private Companies (12/10)

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Delenex Therapeutics AG
  • Senior Management
  • Eric de La Fortelle, PhD, CEO
    Jakob Sclapbach, CFO
    Titus Kretzschmar, PhD, CSO
    Hamish Cameron, MD, Head, Bus. Dev.
  • Contact Info
  • Delenex Therapeutics AG
    Phone: (41) 44-730 5180
    Wagistrasse 23
    Zürich-Schlieren , CH-8952